Hacı Murat GÜNEŞ, Göksel AÇAR, Mehmet Muhsin TÜRKMEN, Ulaankhuu BATGEREL, Zeki ŞİMŞEK, Murat YUKSEL, Ali Metin ESEN

Sirolimus-kaplı stent ile polizen-F polimerli kobalt krom stentin erken dönemde tetiklediği inflamatuvar yanıt ve uzun dönem sonuçlarının karşılaştırılması

Amaç: Perkütan translüminal koroner anjioplasti (PTCA) işleminin erken ve geç dönem sonuçlarında çok önemli iyileşmeler sağlayan stentler ile geç dönemde karşılaşılan en önemli sorun %25-30'lara varan restenoz oranları olmuştur. Bunun üstesinden gelmek için geliştirilen ilaç kaplı stentler (DES), restenoz oranlarını azaltmakla birlikte damar iyileşmesini ve endotelizasyonu bozduğundan stent trombozu riskini önemli ölçüde artırmıştır. Biyoinert bir molekül olan Polizen-F (PzF) polimerleriyle yüzey modifikasyonu uygulanmış yeni nesil stentler anti-inflamatuvar ve anti-trombojenik özelliklerini vurgulayarak piyasaya sürülmüştür. Bu çalışmada PzF polimeriyle kaplı stent ile sirolimus kaplı stent takılan hastaları, erken dönemdeki inflamatuvar yanıtları ve 1 yıllık takipte görülen majör istenmeyen kardiyak olay (MACE) sıklığı bakımından karşılaştırmayı amaçladık. Yöntemler: Stabil koroner arter hastalığı (KAH) tanısıyla PzF polimeri kaplı stent takılan hastalar 1.grubu (n=19), sirolimus kaplı stent takılan hastalar 2.gurubu (n=13) oluşturdu. Hastalardan perkütan koroner girişim (PKG) öncesi (pre-PKG), işlem sonrası 1. ve 10.günde (post-PKG 1. ve post-PKG 10.gün) hsCRP ve IL-6 düzeyi bakıldı. Hastalar ortalama 1 yıl süreyle gelişebilecek MACE sıklığı açısından takip edildi.Bulgular: Pre-PKG, post-PKG 1. ve 10.gündeki hsCRP ve IL-6 düzeyleri bakımından gruplar arasında anlamlı bir fark yoktu. 1.gruptaki19 hastadan 4'ünde (%21) MACE gelişirken, bu oran 2.grupta 13 hastada 1 idi (%8); fakat gruplar arasındaki bu fark istatistiksel olarak anlamlı değildi (p=0,26).Sonuç: Daha az inflamatuvar yanıtı tetiklediği ve anti-trombojenik özelliği iddiasıyla piyasaya sürülen PzF polimeriyle kaplı stent ile sirolimus-kaplı stent arasında tetikledikleri inflamatuvar yanıt belirteçleri ve 1-yıllık MACE oranları bakımından anlamlı bir fark gözlenmedi. Bu konunun aydınlatılması için prospektif, randomize, büyük ölçekli çalışmalara ihtiyaç vardır.

Comparison of sirolimus-eluting stent versus polyzene-F polymer-coated stent in terms of early inflammatory response and long term outcomes

Objective: The intra-coronary stents provided great benefit after percutaneous transluminal coronary angioplasty (PTCA); however, high in-stent restenosis rates, even up to 25-30%, is the the main concern. Cytotoxic drug-eluting stents were developed to overcome this challenge. Whereas, they interfered vessel healing and endothelization process which led to increased risk of stent thrombosis. A bioinert molecule, polyzene-F(PzF), was applied to the surface of a new generation stent to provide anti-inflammatory and antithrombogenic property. We aimed to compare the sirolimuseluting stent with PzF-coated cobalt-chrome stent in terms of early inflammatory response and long-term major adverse cardiac events (MACE) rates. Methods: Stable coronary artery disease patients treated with PzF-coated cobalt-chrome stent formed the 1st group (n=19), and those received sirolimus-eluting stent (n=13) formed the 2nd group. Serum hsCRP and IL-6 levels were measured before percutaneous coronary intervention (prePCI), and after 1st and 10th days (post-PCI 1, and post-PCI 10, respectively) of PCI. The patients were followed-up to 1 year in terms of MACE experience.Results: The study groups were comparable in terms of pre-PCI, post-PCI-1 and post-PCI-10 serum hsCRP and IL-6 levels. Four of 19 patients (21%) in the 1st group and 1 of 13 patients (8%) in the 2nd group experienced MACE during 1-year follow-up; whereas this difference was not statistically significant (p=0.26).Conclusion: Although, the PzF-coated cobalt-chrome stent was claimed to have lower anti-inflammatory and antithrombogenic properties, we showed similar inflammatory response and long-term MACE rates compared to sirolimuseluting stent. Prospective, randomized, large scale studies are needed to clarify this issue. J Clin Exp Invest 2015; 6 (2).

PDF

___

Serruys PW, Degertekin M, Tanabe K, et al. Intravascu- lar ultrasound findings in the multicenter, randomized, double-blind RAVEL (RAndomized study with the sirolimus-eluting Velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial. Circulation 2002;106:798-803.
Richter GM, Stampfl U, Stampfl S, et al. A new poly- mer concept for coating of vascular stents using PT- FEP (poly(bis(trifluoroethoxy)phosphazene) to reduce thrombogenicity and late in-stent stenosis. Invest Ra- diol 2005;40:210-218.
Hill RA, Boland A, Dickson R, et al. Drug-eluting stents: a systematic review and economic evaluation. Health Technol Assess 2007, 11:iii, xi-221.
Fajadet J, Wijns W, Laarman GJ, et al. Randomized, double-blind, multicenter study of the Endeavor zo- tarolimus-eluting stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006;114:798-806.
Morice MC, Serruys PW, Sousa JE, et al. A random- ized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780.
Silber S. Cypher versus taxus: are there differences? J Interv Cardiol 2005;18:441-446.
Moses JW, Leon MB, Popma JJ, et al. Sirolimus- eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323.
Stone GW, Ellis SG, Cox DA et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231.
Virmani R, Guagliumi G, Farb A, et al. Localized hy- persensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004;109:701-705.
McFadden EP, Stabile E, Regar E, et al. Late throm- bosis in drug-eluting coronary stents after discontinu- ation of antiplatelet therapy. Lancet 2004;364:1519- 1521.
Wessely R, Kastrati A, Schomig A. Late restenosis in patients receiving a polymer-coated sirolimus-eluting stent. Ann Intern Med 2005;143:392-394.
Zhang Z, Kolm P, Mosse F, et al. Long-term cost- effectiveness of clopidogrel in STEMI patients. Int J Cardiol 2009;135:353-360.
Grines CL, Bonow RO, Casey DE, Jr. et al. Prevention of premature discontinuation of dual antiplatelet ther- apy in patients with coronary artery stents: a science advisory from the American Heart Association, Ameri- can College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with rep- resentation from the American College of Physicians. J Am Coll Cardiol 2007;49:734-739.
Tamburino C, La Manna A, Di Salvo ME, et al. First-in- man 1-year clinical outcomes of the Catania Coronary Stent System with Nanothin Polyzene-F in de novo native coronary artery lesions: the ATLANTA (Assess- ment of The LAtest Non-Thrombogenic Angioplasty stent) trial. JACC Cardiovasc Interv 2009;2:197-204.
La Manna A, Capodanno D, Cera M, et al. Optical coherence tomographic results at six-month follow- up evaluation of the CATANIA coronary stent system with nanothin Polyzene-F surface modification (from the Assessment of The LAtest Non-Thrombogenic Angioplasty Stent [ATLANTA] trial). Am J Cardiol 2009;103:1551-1555.
Li JJ, Qin XW, Yang XC, et al. Randomized compari- son of early inflammatory response after sirolimus- eluting stent vs bare metal stent implantation in native coronary lesions. Clin Chim Acta 2008;396:38-42.
Kralisz P, Kemona H, Dobrzycki S, et al. Changes in C-reactive protein levels following coronary stent im- plantation depend on the extent of periprocedural ar- terial injury. Kardiol Pol 2006;64:364-371.
Greque GV, Serrano CV, Jr., Strunz CM et al. Prepro- cedural statin therapy, inflammation and myocardial injury in low-risk stable coronary artery disease pa- tients submitted to coronary stent implantation. Cath- eter Cardiovasc Interv 2013.